Published in Oncoimmunology on August 03, 2014
Modulation of APC Function and Anti-Tumor Immunity by Anti-Cancer Drugs. Front Immunol (2015) 0.79
Increased Infiltration of CD8(+) T Cells by Dacarbazine in a Patient with Mucosal Penile Melanoma Refractory to Nivolumab. Ann Dermatol (2016) 0.75
Autophagy-dependent danger signaling and adaptive immunity to poorly immunogenic tumors. Oncotarget (2016) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Immunogenic cell death in cancer therapy. Annu Rev Immunol (2012) 6.59
Breakthrough of the year 2013. Cancer immunotherapy. Science (2013) 5.05
Tumor immunotherapy directed at PD-1. N Engl J Med (2012) 4.43
Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther (2013) 1.22
Tumor-altered dendritic cell function: implications for anti-tumor immunity. Front Immunol (2013) 1.17
The tumoricidal activity of memory CD8+ T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol (2004) 1.10
Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission. J Clin Oncol (2012) 1.06
Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells. Cancer Immunol Res (2014) 0.95
The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. Cancer Immunol Immunother (2014) 0.85